[
  {
    "ts": null,
    "headline": "Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case",
    "summary": "FDA expands the label for Gilead Sciences' CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system lymphoma (PCNSL). The decision removes prior limitations on approval and allows Yescarta to be marketed for this rare, hard to treat cancer. The update marks the first time a CAR T-cell therapy is cleared for use in PCNSL, widening potential access for eligible patients. For investors watching NasdaqGS:GILD, this label expansion aligns with Gilead’s...",
    "url": "https://finnhub.io/api/news?id=1b66a0ef28edd32b2ccf15e10305c50aeee0c405d4806ddc834f284720d0a9ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770847576,
      "headline": "Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case",
      "id": 139050585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FDA expands the label for Gilead Sciences' CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system lymphoma (PCNSL). The decision removes prior limitations on approval and allows Yescarta to be marketed for this rare, hard to treat cancer. The update marks the first time a CAR T-cell therapy is cleared for use in PCNSL, widening potential access for eligible patients. For investors watching NasdaqGS:GILD, this label expansion aligns with Gilead’s...",
      "url": "https://finnhub.io/api/news?id=1b66a0ef28edd32b2ccf15e10305c50aeee0c405d4806ddc834f284720d0a9ab"
    }
  },
  {
    "ts": null,
    "headline": "Exploring the top movers within the S&P500 index during today's session.",
    "summary": "Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.",
    "url": "https://finnhub.io/api/news?id=880b6212e0e4da2e8a8b8b42dd72ed25cc1c7541c331079403f1e0a67b9e91bd",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770840305,
      "headline": "Exploring the top movers within the S&P500 index during today's session.",
      "id": 139048483,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "GILD",
      "source": "ChartMill",
      "summary": "Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.",
      "url": "https://finnhub.io/api/news?id=880b6212e0e4da2e8a8b8b42dd72ed25cc1c7541c331079403f1e0a67b9e91bd"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says",
    "summary": "Gilead Sciences (GILD) is positioned for moderate upside in 2026, supported by expanding HIV sales,",
    "url": "https://finnhub.io/api/news?id=625e3dfaddeed0d9d8d1053d7b608b4243964191874e55d64261715970038baf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828051,
      "headline": "Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says",
      "id": 139046502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) is positioned for moderate upside in 2026, supported by expanding HIV sales,",
      "url": "https://finnhub.io/api/news?id=625e3dfaddeed0d9d8d1053d7b608b4243964191874e55d64261715970038baf"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=4788f8680ce321c9f7194f59ebdccc7fb4527bbe93d5a129a8af04b13a1384b9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770827700,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 139060802,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=4788f8680ce321c9f7194f59ebdccc7fb4527bbe93d5a129a8af04b13a1384b9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
    "summary": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
    "url": "https://finnhub.io/api/news?id=2ed6869450702e0792428a68244aefa074dfc114bd7f5ef971dfe6cef8969c5e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770825923,
      "headline": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
      "id": 139060779,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead Bounds Higher As Analysts Debate The Future Of Its Potential HIV Blockbuster",
      "url": "https://finnhub.io/api/news?id=2ed6869450702e0792428a68244aefa074dfc114bd7f5ef971dfe6cef8969c5e"
    }
  },
  {
    "ts": null,
    "headline": "Software Slump Resumes, Bitcoin Plunges To $66,000: What's Moving Markets Wednesday?",
    "summary": "After three straight rebound sessions, the software selloff resumed Wednesday, with the iShares Tech-Expanded Software Sector ETF (NYSE:IGV)",
    "url": "https://finnhub.io/api/news?id=86e3e71646a0efac3d95158a887cc7686b3c68aa5f085a555b417ed8b0c39622",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770823418,
      "headline": "Software Slump Resumes, Bitcoin Plunges To $66,000: What's Moving Markets Wednesday?",
      "id": 139055553,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Candlestick-Chart-Showing-Falling-Stock-.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "After three straight rebound sessions, the software selloff resumed Wednesday, with the iShares Tech-Expanded Software Sector ETF (NYSE:IGV) ",
      "url": "https://finnhub.io/api/news?id=86e3e71646a0efac3d95158a887cc7686b3c68aa5f085a555b417ed8b0c39622"
    }
  },
  {
    "ts": null,
    "headline": "GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales",
    "summary": "Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.",
    "url": "https://finnhub.io/api/news?id=c72e1fee56b4326377e92e5de56542a7ae0a2ea65b577ba24f601e147b57399d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770822900,
      "headline": "GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales",
      "id": 139046503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.",
      "url": "https://finnhub.io/api/news?id=c72e1fee56b4326377e92e5de56542a7ae0a2ea65b577ba24f601e147b57399d"
    }
  },
  {
    "ts": null,
    "headline": "Diodes, Teradata, Lattice Semiconductor, Micron And Other Big Stocks Moving Higher On Wednesday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=8dffd0cc5cede1b33bc906e63521f9001f9008472e90600dfc755b99450e798a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770817828,
      "headline": "Diodes, Teradata, Lattice Semiconductor, Micron And Other Big Stocks Moving Higher On Wednesday",
      "id": 139055365,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Display-Of-Stock-Market-Quotes.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=8dffd0cc5cede1b33bc906e63521f9001f9008472e90600dfc755b99450e798a"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $118",
    "summary": "RBC Capital  analyst Brian Abrahams   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $103 to $118.",
    "url": "https://finnhub.io/api/news?id=fee6f43943c0d2605bb8d30f9bf5aa97f8cfe2510d0ab1346a62a172b7fbb4af",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815728,
      "headline": "RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $118",
      "id": 139055791,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "RBC Capital  analyst Brian Abrahams   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $103 to $118.",
      "url": "https://finnhub.io/api/news?id=fee6f43943c0d2605bb8d30f9bf5aa97f8cfe2510d0ab1346a62a172b7fbb4af"
    }
  },
  {
    "ts": null,
    "headline": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
    "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
    "url": "https://finnhub.io/api/news?id=c3f43236c5409baca78399ace98cafbf368a215f40146dabaca84d685ea0500d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815475,
      "headline": "Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target",
      "id": 139042313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.",
      "url": "https://finnhub.io/api/news?id=c3f43236c5409baca78399ace98cafbf368a215f40146dabaca84d685ea0500d"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Acadia Healthcare, Vertiv, Moderna, Unity Software, Generac & more",
    "summary": "These are the stocks posting the largest moves in midday trading.",
    "url": "https://finnhub.io/api/news?id=1f475bf4e0bf74fb1b6a473bc5d262c36d598b66b3f0a070434bd15f4b53fdb5",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770813545,
      "headline": "Stocks making the biggest moves midday: Acadia Healthcare, Vertiv, Moderna, Unity Software, Generac & more ",
      "id": 139046199,
      "image": "https://image.cnbcfm.com/api/v1/image/108063804-1731687828868-Vertiv-Photo-OB-MW-20241115-PRESS-6.jpg?v=1731687955&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "These are the stocks posting the largest moves in midday trading. ",
      "url": "https://finnhub.io/api/news?id=1f475bf4e0bf74fb1b6a473bc5d262c36d598b66b3f0a070434bd15f4b53fdb5"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Climbs Nearly 5% Following Strong Quarter, Bullish Analyst Calls",
    "summary": "Gilead Sciences saw a more than 5% rise in stock prices after reporting strong Q4 results and receiving positive ratings and price target increases.",
    "url": "https://finnhub.io/api/news?id=fc3e700d91833596808894fa79627be47dd88cf57eda48a0dfa335d0fce47fdf",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770813377,
      "headline": "Gilead Climbs Nearly 5% Following Strong Quarter, Bullish Analyst Calls",
      "id": 139055792,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Feb-19--2020-Foster-City-----Ca-----Usa-.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Gilead Sciences saw a more than 5% rise in stock prices after reporting strong Q4 results and receiving positive ratings and price target increases.",
      "url": "https://finnhub.io/api/news?id=fc3e700d91833596808894fa79627be47dd88cf57eda48a0dfa335d0fce47fdf"
    }
  },
  {
    "ts": null,
    "headline": "Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $152",
    "summary": "Truist Securities  analyst Gregory Renza   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $145 to $152.",
    "url": "https://finnhub.io/api/news?id=0089bd590704b11f5212d78b1f5d597284c2ca43ee29b48a37fac61b3a85e629",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770812576,
      "headline": "Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $152",
      "id": 139055793,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Truist Securities  analyst Gregory Renza   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $145 to $152.",
      "url": "https://finnhub.io/api/news?id=0089bd590704b11f5212d78b1f5d597284c2ca43ee29b48a37fac61b3a85e629"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
    "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
    "url": "https://finnhub.io/api/news?id=79a57ca5050052fa9ffb252d3547b02d36393490128be34ebf19696fc1b83e57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809340,
      "headline": "These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Humana, Lyft, Mattel, Beta Technologies, Gilead, and More",
      "id": 139041061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares in Moderna tumble after the company says the Food and Drug Administration refuses to review a seasonal flu vaccine application.",
      "url": "https://finnhub.io/api/news?id=79a57ca5050052fa9ffb252d3547b02d36393490128be34ebf19696fc1b83e57"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences shares are trading higher after the company reported better-than-expected Q4 financial results and increased its quarterly dividend. Also, multiple firms raised their respective price targets on the stock.",
    "summary": "Gilead Sciences shares are trading higher after the company reported better-than-expected Q4 financial results and increased its quarterly dividend. Also, multiple firms raised their respective price targets on the stock.",
    "url": "https://finnhub.io/api/news?id=40675c91114966cdc2ed2956bc11a5a47d09cd7c6802fde9b2aca4069e90cefc",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809153,
      "headline": "Gilead Sciences shares are trading higher after the company reported better-than-expected Q4 financial results and increased its quarterly dividend. Also, multiple firms raised their respective price targets on the stock.",
      "id": 139055794,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=40675c91114966cdc2ed2956bc11a5a47d09cd7c6802fde9b2aca4069e90cefc"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $165",
    "summary": "Wells Fargo  analyst Mohit Bansal   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $150 to $165.",
    "url": "https://finnhub.io/api/news?id=f0d1b232dc2b2617d1eeb985afca57026190a2a9626b32e3909d5722c512b8be",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770807446,
      "headline": "Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $165",
      "id": 139055795,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Wells Fargo  analyst Mohit Bansal   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $150 to $165.",
      "url": "https://finnhub.io/api/news?id=f0d1b232dc2b2617d1eeb985afca57026190a2a9626b32e3909d5722c512b8be"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=b9a94595796374695442f731f95d7f85434466588716ed00500432f689fce98a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770803582,
      "headline": "Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings",
      "id": 139043599,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=b9a94595796374695442f731f95d7f85434466588716ed00500432f689fce98a"
    }
  },
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $155",
    "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $135 to $155.",
    "url": "https://finnhub.io/api/news?id=15229b8205ee3aa20107225debccb8e996acf9a4e794be9644309f7b65b29b52",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770803032,
      "headline": "Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $155",
      "id": 139043600,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $135 to $155.",
      "url": "https://finnhub.io/api/news?id=15229b8205ee3aa20107225debccb8e996acf9a4e794be9644309f7b65b29b52"
    }
  },
  {
    "ts": null,
    "headline": "Scotiabank Maintains Sector Outperform on Gilead Sciences, Raises Price Target to $177",
    "summary": "Scotiabank  analyst Louis Chen   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Outperform and raises the price target from $140 to $177.",
    "url": "https://finnhub.io/api/news?id=bac3508c0a81b994970b47fbe15449ad886dea34940672124aa0e804fe6f9b2e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770802123,
      "headline": "Scotiabank Maintains Sector Outperform on Gilead Sciences, Raises Price Target to $177",
      "id": 139043601,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Scotiabank  analyst Louis Chen   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Outperform and raises the price target from $140 to $177.",
      "url": "https://finnhub.io/api/news?id=bac3508c0a81b994970b47fbe15449ad886dea34940672124aa0e804fe6f9b2e"
    }
  },
  {
    "ts": null,
    "headline": "Needham Maintains Buy on Gilead Sciences, Raises Price Target to $170",
    "summary": "Needham  analyst Joseph Stringer   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $140 to $170.",
    "url": "https://finnhub.io/api/news?id=9b36df5756a993e707500484f13a96ce8dbf873b63930c2133bdbf6099265164",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770797115,
      "headline": "Needham Maintains Buy on Gilead Sciences, Raises Price Target to $170",
      "id": 139043602,
      "image": "",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Needham  analyst Joseph Stringer   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $140 to $170.",
      "url": "https://finnhub.io/api/news?id=9b36df5756a993e707500484f13a96ce8dbf873b63930c2133bdbf6099265164"
    }
  },
  {
    "ts": null,
    "headline": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=be869d2f8efd7278df38072ae4e0e1247c376172ecfd2764c6117f6d80648b82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770787876,
      "headline": "GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook",
      "id": 139042314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of $29.8 billion at the midpoint came in 1.2% below analysts’ estimates. Its non-GAAP profit of $1.86 per share was 1.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=be869d2f8efd7278df38072ae4e0e1247c376172ecfd2764c6117f6d80648b82"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
    "url": "https://finnhub.io/api/news?id=29099625c28acafa252ca87b7fc4f50884601dccb12e99a3ef2121b9dd462648",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770786197,
      "headline": "Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
      "id": 139039351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc (GILD) reports robust HIV sales growth and outlines strategic initiatives for 2026, despite facing competitive pressures in cell therapy.",
      "url": "https://finnhub.io/api/news?id=29099625c28acafa252ca87b7fc4f50884601dccb12e99a3ef2121b9dd462648"
    }
  }
]